# A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients

> **NCT00690287** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 24 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** AZD6370
- **DRUG:** AZD6370
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00690287
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2012-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00690287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00690287, "A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00690287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*